Show simple item record

dc.contributor.authorHaanen, JBAGen_US
dc.contributor.authorCarbonnel, Fen_US
dc.contributor.authorRobert, Cen_US
dc.contributor.authorKerr, KMen_US
dc.contributor.authorPeters, Sen_US
dc.contributor.authorLarkin, Jen_US
dc.contributor.authorJordan, Ken_US
dc.contributor.authorESMO Guidelines Committeeen_US
dc.date.accessioned2018-02-16T15:33:43Z
dc.date.issued2017-07en_US
dc.identifier.citationAnnals of oncology : official journal of the European Society for Medical Oncology, 2017, 28 (suppl_4), pp. iv119 - iv142en_US
dc.identifier.issn0923-7534en_US
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/1220
dc.identifier.eissn1569-8041en_US
dc.identifier.doi10.1093/annonc/mdx225en_US
dc.formatPrinten_US
dc.format.extentiv119 - iv142en_US
dc.languageengen_US
dc.language.isoengen_US
dc.subjectESMO Guidelines Committeeen_US
dc.subjectHumansen_US
dc.subjectNeoplasmsen_US
dc.subjectAntibodies, Monoclonalen_US
dc.subjectFollow-Up Studiesen_US
dc.subjectMedical Oncologyen_US
dc.subjectAntibodies, Monoclonal, Humanizeden_US
dc.subjectDrug-Related Side Effects and Adverse Reactionsen_US
dc.subjectAntineoplastic Agents, Immunologicalen_US
dc.subjectIpilimumaben_US
dc.subjectNivolumaben_US
dc.titleManagement of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.en_US
dc.typeJournal Article
rioxxterms.versionofrecord10.1093/annonc/mdx225en_US
rioxxterms.licenseref.startdate2017-07en_US
rioxxterms.typeJournal Article/Reviewen_US
dc.relation.isPartOfAnnals of oncology : official journal of the European Society for Medical Oncologyen_US
pubs.issuesuppl_4en_US
pubs.notesNot knownen_US
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Melanoma and Kidney Cancer
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Melanoma and Kidney Cancer/Melanoma and Kidney Cancer (hon.)
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublisheden_US
pubs.volume28en_US
pubs.embargo.termsNot knownen_US
icr.researchteamMelanoma and Kidney Canceren_US
dc.contributor.icrauthorLarkin, Jamesen_US
dc.contributor.icrauthorMarsden,en_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record